A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT02311998

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:39:04.314218+00:00

Published At

2023-07-17T00:00:00+00:00

Record Updated At

2023-07-17

Results Posted At

2023-07-17

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1", "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Blasts More Than 5 Percent of Bone Marrow Nucleated Cells", "CD22 Positive", "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia", "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2023-07-17"

protocolSection.identificationModule.nctId

"NCT02311998"

protocolSection.identificationModule.officialTitle

"A Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-Positive Philadelphia-Chromosome Positive Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia Lymphoid Blast Phase"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE1", "PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2023-07-17"

Study condition terms

• B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1 (protocolSection.conditionsModule.conditions)
• Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Blasts More Than 5 Percent of Bone Marrow Nucleated Cells (protocolSection.conditionsModule.conditions)
• CD22 Positive (protocolSection.conditionsModule.conditions)
• Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)
• Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.